Clinical Trial Update: A Study of Renal Autologous Cell Therapy (REACT) in Participants With Type 2 Diabetes and Chronic Kidney Disease [Phase 3]

View source ↗

Summary

Prokidney's Phase 3 study of Renal Autologous Cell Therapy (REACT) for type 2 diabetes mellitus and chronic kidney disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• Renal Autologous Cell Therapy (REACT)

Snippet

Sponsor: Prokidney | Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Diseases | Phase 3 | Status: WITHDRAWN